Actively Recruiting
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
Led by Shenzhen People's Hospital · Updated on 2022-11-03
5
Participants Needed
1
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)
CONDITIONS
Official Title
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic heart failure (NYHA grade II-III) with reduced ejection fraction (LVEF 60;40%) and elevated BNP
- Patients on a stable dose of heart failure treatment with no dose changes for at least 4 weeks before screening
- Volunteers willing to participate and provide informed consent
You will not qualify if you...
- Previous continuous use of sacubitril valsartan sodium 150mg twice daily or more for over 3 months
- Use of other study drugs or medical devices within 1 day, 30 days, or 5 half-lives before the visit
- Known or suspected allergy to S086, sacubitril valsartan sodium, ARB, ACEI, or enkephin inhibitor (NEPI), or contraindications to sacubitril valsartan sodium
- History of intolerance to the recommended target dose of ACEI or ARB
- History of angioedema
- Acute coronary syndrome within 6 weeks before the visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shenzhen People' S Hospital
Shenzhen, Guangdong, China, 518000
Actively Recruiting
Research Team
J
junbo he
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here